The Korean Journal of Internal Medicine

Search

Close

2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침

2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침

이정명1, 정보영2, 차명진3, 이지현4, 임우현5, 김태훈2, 신승용6, 엄재선2, 임홍의7, 김진배1, 김준수8

2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation

Jung Myung Lee1, Boyoung Joung2, Myung-Jin Cha3, Ji Hyun Lee4, Woo Hyun Lim5, Tae-Hoon Kim2, Seung Yong Shin6, Jae-Sun Uhm2, Hong Euy Lim7, Jin-Bae Kim1, Jun Soo Kim8
Korean J Med 2018;93:87-109. https://doi.org/10.3904/kjm.2018.93.2.87
다음과 같이 본문 내 Table 5에 오류가 있어 수정합니다.

Table 5.
Guidance for temporary interruption of NOAC before surgery
Dabigatran
Apixaban, edoxaban, rivaroxaban
Low-risk surgery High-risk surgery
Low-risk surgery High-risk surgery
Creatinine clearance >80 mL/min 24 hours 48 hours 24 hours 48 hours
Creatinine clearance 50-80 mL/min 36 hours 72 hours 24 hours 48 hours
Creatinine clearance 30-50 mL/min 48 hours 96 hours 24 hours 48 hours
Creatinine clearance 15-30 mL/min Not indicated Not indicated 36 hours 48 hours

NOAC, non-vitamin K antagonist oral anticoagulant.

Table 5.
Guidance for temporary interruption of NOAC before surgery
Dabigatran
Apixaban, edoxaban, rivaroxaban
Low risk surgery High risk surgery Low risk surgery High risk surgery
Creatinine clearance >80 mL/min 24 hours 48 hours 24 hours 48 hours
Creatinine clearance 50-80 mL/min 36 hours 72 hours 24 hours 48 hours
Creatinine clearance 30-50 mL/min 48 hours 96 hours 24 hours 48 hours
Creatinine clearance 15-30 mL/min Not indicated Not indicated 36 hours 48 hours

NOAC, non-vitamin K antagonist oral anticoagulant.

hanmi ckdpharm. AMGEN
Memo patch yungjin daewoongbio

Go to Top